QiLu’s ALK inhibitor meets Phase III primary endpoint in NSCLC
Concurrent with the success of iruplinalkib, QiLu is conducting other Phase III trials with NSCLC patients.
18 August 2023
18 August 2023
Concurrent with the success of iruplinalkib, QiLu is conducting other Phase III trials with NSCLC patients.
The Phase Ib trial involved antipsychotic-naïve, healthy patients who were initially treated with olanzapine for one week.
BL-001 was well tolerated and showed favourable strain kinetics with its component strains increasing in a dose dependent manner.
As restrictions on abortion drug mifepristone loom, doctors and patients are looking to off-label misoprostol.
NPX267 targets killer cell immunoglobulin-like receptor 3DL3 and helps prevent immune escape in solid tumours.
Top-line data readout of total patients from the study is anticipated in April 2025.
The CE-marked device is being investigated in 84 patients, with primary patency assessed at six-months.
Topline data from the trial is anticipated in the second half of next year.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Give your business an edge with our leading industry insights.